Pembrolizumab Plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Last Updated: Wednesday, August 3, 2022
In an interim analysis of the phase 3 KEYNOTE-355 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed PD-L1 with a combined positive score of 10 or more. The results of the final analysis of overall survival have not been reported.
Advertisement
News & Literature Highlights